{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T10:51:14Z","timestamp":1792061474097,"version":"4.4.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2027,2,1]],"date-time":"2027-02-01T00:00:00Z","timestamp":1801440000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,2,1]],"date-time":"2027-02-01T00:00:00Z","timestamp":1801440000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:00:00Z","timestamp":1791936000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunology Letters"],"published-print":{"date-parts":[[2027,2]]},"DOI":"10.1016\/j.imlet.2026.107247","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:00:44Z","timestamp":1791356444000},"page":"107247","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Exploratory clinical and immunological changes following Tixagevimab\/Cilgavimab administration in immunodeficient patients with SARS-CoV-2-associated ME\/CFS and persistent circulating spike protein"],"prefix":"10.1016","volume":"283","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0029-8663","authenticated-orcid":false,"given":"Maximilian","family":"Seidel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moritz","family":"Anft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7520-2247","authenticated-orcid":false,"given":"Lea","family":"Wiemers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix S.","family":"Seibert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Bertram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6926-7227","authenticated-orcid":false,"given":"Kamil","family":"Rosiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2831-8868","authenticated-orcid":false,"given":"Ulrik","family":"Stervbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timm H.","family":"Westhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3673-712X","authenticated-orcid":false,"given":"Nina","family":"Babel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.imlet.2026.107247_bib0001","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1056\/NEJMoa2403211","article-title":"Postacute sequelae of SARS-CoV-2 infection in the Pre-Delta, Delta, and Omicron Eras","volume":"391","author":"Xie","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.imlet.2026.107247_bib0002","article-title":"A clinical case definition of post-COVID-19 condition by a Delphi consensus - PubMed","volume":"22","author":"JB","year":"2022","journal-title":"Lancet Infect. Dis."},{"issue":"11","key":"10.1016\/j.imlet.2026.107247_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2023.103445","article-title":"Severity of neurological long-COVID symptoms correlates with increased level of autoantibodies targeting vasoregulatory and autonomic nervous system receptors","volume":"22","author":"Seibert","year":"2023","journal-title":"Autoimmun. Rev."},{"issue":"1","key":"10.1016\/j.imlet.2026.107247_bib0004","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/s41591-024-03309-8","article-title":"Posthospitalization COVID-19 cognitive deficits at 1\u2009year are global and associated with elevated brain injury markers and gray matter volume reduction","volume":"31","author":"Wood","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.imlet.2026.107247_bib0005","first-page":"499","article-title":"Immune adsorption for the treatment of fatigue-dominant long-\/post-COVID syndrome - PubMed","volume":"120","author":"J","year":"2023","journal-title":"Dtsch. Arztebl. Int."},{"issue":"6","key":"10.1016\/j.imlet.2026.107247_bib0006","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1016\/j.ymthe.2025.01.007","article-title":"Effect of immunoadsorption on clinical presentation and immune alterations in COVID-19-induced and\/or aggravated ME\/CFS","volume":"33","author":"Anft","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.imlet.2026.107247_bib0007","article-title":"SARS-CoV-2 RNA detection in cerebrospinal fluid: presentation of two cases and review of literature","volume":"15","author":"Luis","year":"2021","journal-title":"Brain Behav. Immun. Health"},{"issue":"7","key":"10.1016\/j.imlet.2026.107247_bib0008","doi-asserted-by":"crossref","first-page":"e453","DOI":"10.1016\/S1473-3099(23)00815-0","article-title":"Persistent SARS-CoV-2 infection: significance and implications","volume":"24","author":"Machkovech","year":"2024","journal-title":"Lancet Infect. Dis."},{"issue":"8001","key":"10.1016\/j.imlet.2026.107247_bib0009","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1038\/s41586-024-07029-4","article-title":"Prevalence of persistent SARS-CoV-2 in a large community surveillance study","volume":"626","author":"Ghafari","year":"2024","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.imlet.2026.107247_bib0010","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s12879-022-07153-4","article-title":"Post-COVID-19 syndrome. SARS-CoV-2 RNA detection in plasma, stool, and urine in patients with persistent symptoms after COVID-19","volume":"22","author":"Tejerina","year":"2022","journal-title":"BMC. Infect. Dis."},{"issue":"8","key":"10.1016\/j.imlet.2026.107247_bib0011","doi-asserted-by":"crossref","first-page":"e78","DOI":"10.1016\/S2213-2600(21)00240-X","article-title":"Persistence of SARS-CoV-2 RNA in lung tissue after mild COVID-19","volume":"9","author":"Ceulemans","year":"2021","journal-title":"Lancet Respir. Med."},{"issue":"2","key":"10.1016\/j.imlet.2026.107247_bib0012","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.28568","article-title":"Persistent circulation of soluble and extracellular vesicle-linked Spike protein in individuals with postacute sequelae of COVID-19","volume":"95","author":"Craddock","year":"2023","journal-title":"J. Med. Virol."},{"issue":"4","key":"10.1016\/j.imlet.2026.107247_bib0013","doi-asserted-by":"crossref","first-page":"44","DOI":"10.7812\/TPP\/22.180","article-title":"Safety and efficacy of intramuscular Tixagevimab-Cilgavimab in prevention of COVID-19 in patients who are immunocompromised","volume":"27","author":"Moon","year":"2023","journal-title":"Perm. J."},{"issue":"3","key":"10.1016\/j.imlet.2026.107247_bib0014","doi-asserted-by":"crossref","DOI":"10.36519\/idcm.2023.248","article-title":"Long-term symptoms and quality of life in persons with COVID-19","volume":"5","author":"Yal\u00e7\u0131n-\u00c7olak","year":"2023","journal-title":"Infect. Dis. Clin. Microbiol."},{"issue":"1","key":"10.1016\/j.imlet.2026.107247_bib0015","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-34678-8","article-title":"Impaired health-related quality of life in long-COVID syndrome after mild to moderate COVID-19","volume":"13","author":"Malesevic","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.imlet.2026.107247_bib0016","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2022.975992","article-title":"What is the quality of life in patients with long COVID compared to a healthy control group?","volume":"10","author":"L\u00ed\u0161ka","year":"2022","journal-title":"Front. Public Health"},{"key":"10.1016\/j.imlet.2026.107247_bib0017","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ajem.2023.09.051","article-title":"Remission of severe forms of long COVID following monoclonal antibody (MCA) infusions: a report of signal index cases and call for targeted research","volume":"75","author":"Scheppke","year":"2024","journal-title":"Am. J. Emerg. Med."},{"issue":"3","key":"10.1016\/j.imlet.2026.107247_bib0018","doi-asserted-by":"crossref","first-page":"e487","DOI":"10.1093\/cid\/ciac722","article-title":"Persistent circulating severe acute Respiratory syndrome coronavirus 2 spike is associated with post-acute coronavirus disease 2019 sequelae","volume":"76","author":"Swank","year":"2023","journal-title":"Clin. Infect. Dis."},{"issue":"11","key":"10.1016\/j.imlet.2026.107247_bib0019","doi-asserted-by":"crossref","first-page":"3518","DOI":"10.3390\/jcm9113518","article-title":"The role of molecular chaperones in virus infection and implications for understanding and treating COVID-19","volume":"9","author":"Paladino","year":"2020","journal-title":"J. Clin. Med."},{"issue":"4","key":"10.1016\/j.imlet.2026.107247_bib0020","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1089\/aid.2020.0161","article-title":"What HIV in the brain can teach us about SARS-CoV-2 neurological complications?","volume":"37","author":"Al-Harthi","year":"2021","journal-title":"AIDS Res. Hum. Retroviruses"},{"issue":"7","key":"10.1016\/j.imlet.2026.107247_bib0021","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/s41590-021-00962-w","article-title":"SARS-CoV-2 takes its toll","volume":"22","author":"Sariol","year":"2021","journal-title":"Nat. Immunol."},{"issue":"2","key":"10.1016\/j.imlet.2026.107247_bib0022","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.00333-23","article-title":"Molecular characterization of AZD7442 (Tixagevimab-Cilgavimab) neutralization of SARS-CoV-2 omicron subvariants","volume":"11","author":"Roe","year":"2023","journal-title":"Microbiol. Spectr."},{"issue":"1","key":"10.1016\/j.imlet.2026.107247_bib0023","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-47176-w","article-title":"Incident allergic diseases in post-COVID-19 condition: multinational cohort studies from South Korea, Japan and the UK","volume":"15","author":"Oh","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.imlet.2026.107247_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtauto.2021.100100","article-title":"Functional autoantibodies against G-protein coupled receptors in patients with persistent Long-COVID-19 symptoms","volume":"4","author":"Wallukat","year":"2021","journal-title":"J. Transl. Autoimmun."},{"issue":"12","key":"10.1016\/j.imlet.2026.107247_bib0025","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1016\/j.pain.2011.06.012","article-title":"Autoimmunity against the beta2 adrenergic receptor and muscarinic-2 receptor in complex regional pain syndrome","volume":"152","author":"Kohr","year":"2011","journal-title":"Pain"},{"issue":"4","key":"10.1016\/j.imlet.2026.107247_bib0026","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.3390\/ijms25042299","article-title":"Autoantibodies targeting G-protein-coupled receptors: pathogenetic, clinical and therapeutic implications in systemic sclerosis","volume":"25","author":"Binda","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.imlet.2026.107247_bib0027","first-page":"14","article-title":"When natural antibodies become pathogenic: autoantibodies targeted against G protein-coupled receptors in the pathogenesis of systemic sclerosis","author":"Akbarzadeh","year":"2023","journal-title":"Front. Immunol."},{"issue":"10","key":"10.1016\/j.imlet.2026.107247_bib0028","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1161\/01.RES.0000102042.83024.CA","article-title":"What is the role of beta-adrenergic signaling in heart failure?","volume":"93","author":"Lohse","year":"2003","journal-title":"Circ. Res."},{"key":"10.1016\/j.imlet.2026.107247_bib0029","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1093\/eurheartj\/12.suppl_D.178","article-title":"Autoantibodies against the beta-adrenergic receptor in human myocarditis and dilated cardiomyopathy: beta-adrenergic agonism without desensitization","volume":"12","author":"Wallukat","year":"1991","journal-title":"Eur. Heart. J."},{"key":"10.1016\/j.imlet.2026.107247_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtauto.2019.100006","article-title":"A functional cell-based bioassay for assessing adrenergic autoantibody activity in postural tachycardia syndrome","volume":"2","author":"Badiudeen","year":"2019","journal-title":"J. Transl. Autoimmun."},{"issue":"23","key":"10.1016\/j.imlet.2026.107247_bib0031","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1056\/NEJMoa2116620","article-title":"Intramuscular AZD7442 (Tixagevimab\u2013Cilgavimab) for prevention of covid-19","volume":"386","author":"Levin","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.imlet.2026.107247_bib0032","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.bbi.2024.10.006","article-title":"A review of intravenous immunoglobulin in the treatment of neuroimmune conditions, acute COVID-19 infection, and post-acute sequelae of COVID-19 Syndrome","volume":"123","author":"Morse","year":"2025","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.imlet.2026.107247_bib0033","article-title":"Long-term high-dose immunoglobulin successfully treats Long COVID patients with pulmonary, neurologic, and cardiologic symptoms","volume":"13","author":"Thompson","year":"2022","journal-title":"Front. Immunol."},{"issue":"13","key":"10.1016\/j.imlet.2026.107247_bib0034","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2109682","article-title":"Subcutaneous REGEN-COV antibody combination to prevent covid-19","volume":"385","author":"O\u2019Brien","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.imlet.2026.107247_bib0035","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/S1473-3099(22)00416-9","article-title":"Efficacy and safety of a single dose of casirivimab and imdevimab for the prevention of COVID-19 over an 8-month period: a randomised, double-blind, placebo-controlled trial","volume":"22","author":"Herman","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.imlet.2026.107247_bib0036","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1093\/cid\/ciaf265","article-title":"Safety and efficacy of Pemivibart, a long-acting monoclonal antibody, for prevention of symptomatic coronavirus disease 2019: interim results from a phase 3 randomized clinical trial (CANOPY)","volume":"81","author":"Wolfe","year":"2025","journal-title":"Clin. Infect. Dis."},{"issue":"7","key":"10.1016\/j.imlet.2026.107247_bib0037","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofad314","article-title":"Prevention of COVID-19 following a single intramuscular administration of Adintrevimab: results from a phase 2\/3 randomized, double-blind, placebo-controlled trial (EVADE)","volume":"10","author":"Ison","year":"2023","journal-title":"Open. Forum. Infect. Dis."}],"container-title":["Immunology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165247826001215?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165247826001215?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T10:24:59Z","timestamp":1792059899000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165247826001215"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,2]]},"references-count":37,"alternative-id":["S0165247826001215"],"URL":"https:\/\/doi.org\/10.1016\/j.imlet.2026.107247","relation":{},"ISSN":["0165-2478"],"issn-type":[{"value":"0165-2478","type":"print"}],"subject":[],"published":{"date-parts":[[2027,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploratory clinical and immunological changes following Tixagevimab\/Cilgavimab administration in immunodeficient patients with SARS-CoV-2-associated ME\/CFS and persistent circulating spike protein","name":"articletitle","label":"Article Title"},{"value":"Immunology Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.imlet.2026.107247","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of European Federation of Immunological Societies.","name":"copyright","label":"Copyright"}],"article-number":"107247"}}